Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claude Negrier

Showing results (41-50 of 61) with videos related to

Pageof 7
Sort By:
Journal of Thrombosis and Haemostasis : JTH|July 16, 2020
Hypofibrinolytic state and high thrombin generation may play a major role in SARS-COV2 associated thrombosisChristophe Nougier, Remi Benoit, Marie Simon, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 14, 2026
florio HAEMO-A Digital Medical Device for Monitoring of Treatment, Symptoms and Physical Activities for People Living With HaemophiliaChristoph Königs, Jan Astermark, Jan Blatny, et al.
British Journal of Haematology|September 28, 2007
Effect of standardization and normalization on imprecision of calibrated automated thrombography: an international multicentre studyYesim Dargaud, Rodger Luddington, Elaine Gray, et al.
Thrombosis Research|December 28, 2013
Effect of pre-analytical conditions on the thrombodynamics assayNatalia M Dashkevich, Tatiana A Vuimo, Ruzanna A Ovsepyan, et al.
Blood|September 13, 2003
Deletion of alanine 2201 in the FVIII C2 domain results in mild hemophilia A by impairing FVIII binding to VWF and phospholipids and destroys a major FVIII antigenic determinant involved in inhibitor developmentRoseline d'Oiron, Jean-Maurice Lavergne, Renaud Lavend'homme, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 18, 2019
BAY 94-9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim resultsShadan Lalezari, Mark T Reding, Ingrid Pabinger, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 30, 2023
A global comparative field study to evaluate the factor VIII activity of efanesoctocog alfa by one-stage clotting and chromogenic substrate assays at clinical haemostasis laboratoriesSteven Pipe, Ali Sadeghi-Khomami, Barbara A Konkle, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 5, 2021
Confirmed long-term safety and efficacy of prophylactic treatment with BAY 94-9027 in severe haemophilia A: final results of the PROTECT VIII extension studyMark T Reding, Ingrid Pabinger, Pal Andre Holme, et al.
British Journal of Haematology|September 12, 2014
Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding ratesJerry Powell, Amy Shapiro, Margaret Ragni, et al.
Gene Therapy|February 15, 2024
Multicenter assessment and longitudinal study of the prevalence of antibodies and related adaptive immune responses to AAV in adult males with hemophiliaIngrid Pabinger, Mila Ayash-Rashkovsky, Miguel Escobar, et al.
Pageof 7

Showing results (41-50 of 61) with videos related to

Sort By:
Pageof 7
Journal of Thrombosis and Haemostasis : JTH|July 16, 2020
Hypofibrinolytic state and high thrombin generation may play a major role in SARS-COV2 associated thrombosisChristophe Nougier, Remi Benoit, Marie Simon, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 14, 2026
florio HAEMO-A Digital Medical Device for Monitoring of Treatment, Symptoms and Physical Activities for People Living With HaemophiliaChristoph Königs, Jan Astermark, Jan Blatny, et al.
British Journal of Haematology|September 28, 2007
Effect of standardization and normalization on imprecision of calibrated automated thrombography: an international multicentre studyYesim Dargaud, Rodger Luddington, Elaine Gray, et al.
Thrombosis Research|December 28, 2013
Effect of pre-analytical conditions on the thrombodynamics assayNatalia M Dashkevich, Tatiana A Vuimo, Ruzanna A Ovsepyan, et al.
Blood|September 13, 2003
Deletion of alanine 2201 in the FVIII C2 domain results in mild hemophilia A by impairing FVIII binding to VWF and phospholipids and destroys a major FVIII antigenic determinant involved in inhibitor developmentRoseline d'Oiron, Jean-Maurice Lavergne, Renaud Lavend'homme, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 18, 2019
BAY 94-9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim resultsShadan Lalezari, Mark T Reding, Ingrid Pabinger, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 30, 2023
A global comparative field study to evaluate the factor VIII activity of efanesoctocog alfa by one-stage clotting and chromogenic substrate assays at clinical haemostasis laboratoriesSteven Pipe, Ali Sadeghi-Khomami, Barbara A Konkle, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 5, 2021
Confirmed long-term safety and efficacy of prophylactic treatment with BAY 94-9027 in severe haemophilia A: final results of the PROTECT VIII extension studyMark T Reding, Ingrid Pabinger, Pal Andre Holme, et al.
British Journal of Haematology|September 12, 2014
Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding ratesJerry Powell, Amy Shapiro, Margaret Ragni, et al.
Gene Therapy|February 15, 2024
Multicenter assessment and longitudinal study of the prevalence of antibodies and related adaptive immune responses to AAV in adult males with hemophiliaIngrid Pabinger, Mila Ayash-Rashkovsky, Miguel Escobar, et al.
Pageof 7